PHVS Reiterate Market Outperform, $74 PT into Ph3 CHAPTER-3 trial of deucrictibant for HAE attack prophylaxis @ Citizens

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.